Home | Pharma Manufacturing

9/28/2026

The share of newer FDA-approved innovator and biosimilar products whose production mix included a Chinese facility is rising, says data and analytics firm.

9/25/2026

Lilly broke ground this week on a $6.5 billion active pharmaceutical ingredient facility that will make Foundayo, while Novo is expanding its oral Wegovy capacity.

9/24/2026

Manufacturers face persistent data and technology transfer challenges that limit the industry’s ability to deploy advanced at-scale applications.

9/23/2026

Contract manufacturers such as Bachem are strengthening their European footprints as suppliers of peptide and oligonucleotide active ingredients, says analytics firm.

9/22/2026

The Danish drugmaker plans to scale production capacity to supply oral obesity therapies to 15 million patients globally by the end of the decade.

9/21/2026

The plant, which is operational and pending regulatory approval, will produce antigen for Sanofi’s high-dose influenza vaccine for Canada and other countries.

9/18/2026

Researchers are using machine learning and real-time process monitoring to improve bioreactor control and help manufacturers automate manual processes.

9/17/2026

BMS said the system could not meet requirements to make commercial Breyanzi. Cellares claims it has manufactured GMP drug product in an FDA-regulated clinical program.

9/16/2026

Thermo Fisher’s pharma services business benefits initially from policy and tariff impacts, as domestic investment in existing and new facilities ramps up, he contends.

9/15/2026

Under a deal worth $120 million over 10 years, Ori’s IRO platform will be integrated into an undisclosed company’s commercial cell therapy production process.

9/14/2026

The biopharma company continues to scale its production capabilities to support a growing portfolio of pharmaceuticals, vaccines, and biologics.

9/11/2026

Customers of outsourced services are putting greater emphasis on reliability, execution, and cost competitiveness, according to consulting firm McKinsey & Company.

9/10/2026

The CDMO says the improved capital structure gives the company even greater ability to invest in its people, capabilities, network, and customer partnerships.

9/9/2026

Under the Bio100 initiative, the company will invest about $300 million in a new drug substance facility in Slovenia to expand its biosimilar manufacturing capacity.

9/8/2026

Specialized facilities, lengthy construction timelines, and workforce constraints could complicate the radiopharmaceutical industry’s path to commercial scale.

9/4/2026

Recent site upgrades, acquisitions, and new partnerships demonstrate a shift from cost-driven outsourcing to integrated, locally anchored models, says the firm.

9/3/2026

The company is investing approximately $108 million in a new drug product facility in Vancouver, Canada, and $100 million to modernize its Indiana API manufacturing site.

9/2/2026

Five teams will create automated platforms capable of producing RNA-based genetic medicines and performing quality control testing at or near the point of care.

9/1/2026

The drugmakers pledged to invest $19.6 billion collectively in U.S. manufacturing and provide discounts on select medicines in exchange for tariff exemptions.

8/31/2026

Bioreactor automation and control systems grow to 38.6% adoption or planned implementation, finds 2026 annual report and survey by BioPlan Associates.

8/28/2026

The CDMO plans to allocate most of offering proceeds toward its PolyPeptide Group acquisition, with the remaining funds slated for Bio Campus II investment.

8/27/2026

The Chinese CRDMO is boosting manufacturing capacity globally through continued investments in China, Singapore, and the United States.

8/26/2026

Scheduled to tour the company’s flagship “smart factory” in Bridgewater this week, it was called off after losing Bristol Myers Squibb as a customer.

8/25/2026

The loss is forcing the automated cell therapy manufacturer to resize, despite doubling the number of customers in 2026.

8/24/2026

The increase was primarily attributable to growth in the CRDMO’s number of customers and projects, driven by antibody-drug conjugates and the broader bioconjugate market.

8/21/2026

With three newly acquired sites, the company contends it is well positioned to support customers from early phase development to commercial manufacturing.

8/20/2026

The CRL relates to Good Manufacturing Practice observations at third-party manufacturer NerPharMa, and a request for additional commercial-scale consecutive batch data.

8/19/2026

As pipelines expand and technical challenges mount, sponsors are increasingly relying on outsourcing partners well before commercialization.

8/18/2026

Germany is at the greatest commercial risk from Washington’s onshoring policies that may trigger tariff and non-tariff measures, warns the data and analytics firm.

8/17/2026

The CDMO’s recent investments are meant to better support customers across the lifecycle of their products, from early development to commercial manufacturing.

8/14/2026

The CDMO’s new sterile fill-finish platform includes a 10-head Groninger filling line designed for production efficiency and regulatory compliance.

8/13/2026

The agency wants to increase the fee starting in fiscal 2028 for all foreign API, finished dosage form, and contract manufacturing organization facilities.

8/12/2026

The CDMO’s new platform reflects a broader shift toward using artificial intelligence to help teams manage increasingly complex manufacturing data.

8/11/2026

Branded a “Chinese military” company by the Department of Defense, the CRDMO secured a legal victory last week against the 1260H designation, but the damage is done.

8/10/2026

Part of a $40 billion U.S. investment, the Texas site will manufacture multiple medicines including antibody-drug conjugates, biologics, and small molecules.

8/10/2026

In response, Scholar Rock will remove the Bloomington fill-finish facility from its Biologics License Application with the agency and rely on a third-party provider.

8/8/2026

Court grants the China-headquartered CRDMO’s motion for preliminary injunction to enjoin Department of Defense from enforcing or implementing 1260H list designation.

8/7/2026

Proponents say using fermentation processes can help reduce America’s reliance on China and India for key starting materials and active pharmaceutical ingredients.

8/6/2026

Manufacturers are expanding capacity while adopting automation, isolator technology, and new workforce strategies to meet increasing demands.

8/5/2026

The company expects contractual fill-finish demand from its largest customer to double beginning in 2027 and grow by more than 200% in 2028, compared to 2026.

8/4/2026

The China-headquartered CRDMO has raised its 2026 CapEx guidance for infrastructure investments, including initiation of a new Changzhou site ahead of schedule.

8/3/2026

The CDMO reported stable manufacturing operations across Plants 1 through 4 in South Korea, as the company expands its global footprint.

7/31/2026

The Switzerland-headquartered CDMO is investing about $618 million in a greenfield project in Sisslerfeld, while ramping up Building K operations in Bubendorf.

7/30/2026

At the company’s Stein facility, the contract development and manufacturing organization is building a second commercial aseptic antibody-drug conjugate filling line.

7/29/2026

Private equity ‌group Apax Funds will buy Gerresheimer’s 15 manufacturing sites for primary plastic packaging in nine countries and Centor’s U.S. production site.

7/28/2026

Manufacturers are increasingly looking to automation, robotics, and connected systems to overcome the limitations of manual production.

7/27/2026

CEO Marc Casper says the company’s DynaDrive single-use bioreactor platform is becoming the “favored” technology for efficient, scalable bioproduction.

7/24/2026

Join this webinar to discover how data orchestration and Digital Threads provide the trusted context needed to scale Industrial AI, accelerate Smart Manufacturing, and drive measurable operational results.

7/24/2026

While generic pharmaceutical products made outside the U.S. remain tariff-free for the time being, the rate could be raised to as much as a 200% duty.

7/24/2026

While generic pharmaceutical products made outside the U.S. remain tariff-free for the time being, the rate could be raised to as much as a 200% duty.

7/23/2026

Aspen and Veranova are also among the leading contract manufacturers for high-potency active pharmaceutical ingredients, according to the data and analytics firm.

7/22/2026

Kansas-Missouri’s $34 million will translate biologic discoveries into U.S. production, while Virginia’s $16 million will develop and scale pharmaceutical manufacturing.

7/21/2026

Designed around uninterrupted operation, automation, and sustainability, the site offers a blueprint for the next generation of commercial autologous manufacturing.

7/20/2026

The acquisition is meant to expand Samsung’s contract development and manufacturing organization capabilities with the addition of peptide production.

7/17/2026

The legislation aims to increase visibility of foreign supply sources amid what they warn is a “growing foothold” in domestic pharmaceutical manufacturing.

7/16/2026

Under the program, Johnson & Johnson Innovative Medicine will exit undisclosed production locations as part of its optimization efforts to streamline operations.

7/15/2026

The companies will explore a next-generation drug innovation model by linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution.

7/14/2026

Funding trends, product pipelines, and the pace of R&D spending indicate demand is “poised to improve materially” for the rest of 2026, contend William Blair analysts.

7/13/2026

The agency’s proposal seeks to streamline registration for advanced distributed manufacturers, while improving foreign supply chain transparency.

7/10/2026

The Indian drugmaker reported certain batches were out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.

7/9/2026

As one of seven companies picked for the pilot, the integrated development and manufacturing organization says regulatory engagement cuts commercialization risk.

7/8/2026

On the heels of closing six facilities in 2025, the company has moved its headquarters from San Diego to Ohio with a biologics and aseptic drug product manufacturing focus.

7/7/2026

As priorities evolve, single-use technologies are enabling more flexible facilities, hybrid manufacturing strategies, and the next generation of biopharmaceutical production.

7/6/2026

The most recent full-year data show a widening gap between the use of European and U.S. facilities, with the first half of 2026 continuing that trend, finds analytics firm.

7/2/2026

With rising demand and the complexities of manufacturing oligo-based therapies, contract developers and manufacturers stand to benefit from the sector’s expansion.

7/1/2026

The Edgmont, Pennsylvania campus is co-located with regional rep Eastern Controls Inc. to deliver faster, more comprehensive support in the mid-Atlantic market.

6/30/2026

The agency selected contract manufacturers Cellares and Fujifilm Biotechnologies, as well as Big Pharma drugmakers Eli Lilly and Regeneron, for the pilot’s initial cohort.

6/29/2026

The Coalition for Epidemic Preparedness Innovations wants to leverage artificial intelligence to speed up the production of vaccines, but there are biosecurity risks.

6/26/2026

Both CRDMOs were accused of ties to China’s government, yet only WuXi AppTec was recently added to the Pentagon list of “Chinese military companies” operating in the U.S.

6/25/2026

The integration of chemical engineering into process development has transformed how companies scale, control, and optimize manufacturing for a new generation of therapies.

6/24/2026

In the space of three weeks, the company has announced four separate antibody-drug conjugate deals with AmMax Bio, Antharis Therapeutics, InduPro, and Stipple Bio.

6/23/2026

Chinese biopharma companies lead when it comes to manufacturing scale, CDMO capacity, and raw materials, according to analyses from the Cure Innovation Index.

6/22/2026

The 120,000-liter Plant 1 facility at the CDMO’s Songdo Bio Campus in Incheon is slated for full-scale commissioning and production system validation later this year.

6/19/2026

With automation holding great potential for cell therapy production, the companies continue to raise capital in a race to scale infrastructure to GMP standards.

6/18/2026

The U.S. Department of Defense has inflicted substantial reputational, commercial, and operational damage to the China-headquartered CRDMO, according to its lawsuit.

6/17/2026

While pharmaceutical companies are investing in artificial intelligence, implementation remains the biggest challenge, according to data and analytics firm GlobalData.

6/16/2026

As a wholly owned subsidiary of Lupin Limited, the company is creating a customer-facing organization with an external service and trusted outsourcing partner mindset.

6/15/2026

WuXi’s designation as a Chinese military company by the U.S. Department of Defense could mean more business for Indian companies in the CRDMO space.

6/12/2026

The China-headquartered CRDMO filed a complaint with the U.S. District Court for the District of Columbia challenging the designation by the Defense Department.

6/11/2026

The pharmaceutical giant is leveraging artificial intelligence to scale production and optimize the efficiency of operations to meet high demand for its medicines.

6/10/2026

According to US Pharmacopeia, supply chain reliance on domestic and foreign facilities for everything from materials to final products is creating single points of failure.

6/9/2026

The Department of Defense says the China-based contract research, development, and manufacturing organization is indirectly affiliated with the People’s Liberation Army.

6/8/2026

The fill-finish facility in Bloomington, formerly owned by Catalent, was cited for eight observations including persistent contamination and quality systems deficiencies.

6/5/2026

Bureau of Labor Statistics forecasts pharmaceutical manufacturing will add nearly 19,000 production jobs, ranking among the fastest-growing industries.

6/3/2026

Citing the current policy direction in Germany, Lilly is reducing by at least 50% the scope of its capital expenditure project in Alzey, Rhineland-Palatinate.

6/3/2026

The draft guidance allows developers to leverage chemistry, manufacturing and controls data, as well as nonclinical and clinical information from ⁠other relevant products.

6/2/2026

Industry stakeholders support the agency’s effort to engage manufacturers earlier in facility development, but uncertainty remains on how the program will be implemented.

6/1/2026

While the biologics market is experiencing strong growth, particularly antibody-drug conjugates, it also poses significant production challenges for the industry.

5/28/2026

Isotope producers and contract development and manufacturing organizations are scaling up production capacity to meet the growing market demand.

5/27/2026

Under the agreement, the Switzerland-headquartered CDMO will acquire AmbioPharm’s two manufacturing facilities in North Augusta, South Carolina and Shanghai, China.

5/26/2026

The company is actively supporting customer reshoring, which is first targeted in its CDMO business and then more broadly in bioproduction and analytical instruments.

5/22/2026

While Lilly’s investment may be one of the largest pharmaceutical buildouts, the construction and operational challenges that it faces aren’t unique.

5/21/2026

With Big Pharma’s pledge of more than $500 billion to U.S. manufacturing and research, industrial production growth should improve over the next several years, says Newmark.

5/20/2026

The CDMO is making progress with the production of different GMP batches, while a revenue growth contribution is expected to begin in the second half of 2026.

5/19/2026

The privately-owned pharmaceutical development and manufacturing organization points to long-term investment as a continued driver of its expansion.

5/18/2026

The CRDMO is adding new drug substance and drug product manufacturing capacity in Asia, Europe, and the U.S. — including a 1.74 million-square-foot plant in Delaware.

5/15/2026

A wave of facility sales to CDMOs reflects shifting manufacturing strategies as drugmakers expand U.S. production and outsourcing partners scale capacity, the firm says.

5/14/2026

The provisional agreement aims to strengthen pharmaceutical manufacturing and reduce the European Union’s dependence on foreign drug suppliers.

5/13/2026

Accenture found that 64% of 2024 drug-launch delays stemmed from CMC issues, highlighting mounting pressure on manufacturers to modernize operations.

5/12/2026

Workforce growth, logistics infrastructure, and education investments are solidifying the area’s position as an up-and-coming cluster in North Carolina.